InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,689.99
(
0.75%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: jbog post# 34086

Thursday, 09/12/2013 9:24:12 AM

Thursday, September 12, 2013 9:24:12 AM

Post# of 80490
Not just oral but presentation but "not to be missed"...

Scroll down to Lung Cancer - Metastatic and Localised/Systemic

http://eccamsterdam2013.ecco-org.eu/Event-Overview/Abstracts-not-to-be-missed.aspx

Also today's abstract does include 5 additional patients (4 ALK/ 1 EGFR)from the ASCO abstract, so a press release is warranted. ALK+ responses increased from 56% at ASCO to 62% (note this includes all doses). In ALK+ with prior Crizotinib (case for imminent pivotal trial) responses increase from 67% to 73%. No additional response from EGFR patient.

Longest response increased from 40 weeks to 48, ongoing. Five more months of data will be presented at ESMO.

No abstracts for LDK, Chugai, or Clovis, but new drug TSR-011 is threatening to be competitive.


Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up